Document is current
Any future updates will be listed below
-
Authors
Hoelzgen, Fabian
Nguyen, Thuy T. P.
Klukin, Elina
Boumaiza, Mohamed
Srivastava, Ayush K.
Kim, Elizabeth Y.
Zalk, Ran http://orcid.org/0000-0003-4251-6497
Shahar, Anat
Cohen-Schwartz, Sagit
Meyron-Holtz, Esther G.
Bou-Abdallah, Fadi http://orcid.org/0000-0002-8557-1827
Mancias, Joseph D. http://orcid.org/0000-0002-0692-3717
Frank, Gabriel A. http://orcid.org/0000-0001-8379-5133
-
Funding
Funding for this research was provided by:
Israel Science Foundation (364/20)
United States - Israel Binational Science Foundation (2022614)
National Science Foundation (2231900)
U.S. Department of Health & Human Services | National Institutes of Health (R01-DK124384)
- License Information
-
More Information
Article History
Received: 14 November 2023
Accepted: 19 April 2024
First Online: 7 May 2024
Competing interests
: GAF and JDM hold the pending provisional patent application 63/534,363 for modulating ferritinophagy based on the structure and mutants described in this paper. JDM reports research support from Novartis and Casma Therapeutics and has consulted for Third Rock Ventures and Skyhawk Therapeutics, all unrelated to the submitted work. All other authors declare no conflict of interest.
